Cover Image
市場調查報告書

C型肝炎病毒 (HCV) 治療藥 - 全球醫藥品的預測與市場分析

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 479774
出版日期 內容資訊 英文 499 Pages
訂單完成後即時交付
價格
Back to Top
C型肝炎病毒 (HCV) 治療藥 - 全球醫藥品的預測與市場分析 PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025
出版日期: 2016年12月06日 內容資訊: 英文 499 Pages
簡介

全球主要9個國家 (美國、法國、德國、義大利、西班牙、英國、日本、巴西、中國) 的C型肝炎的市場規模,2015年為217億美元,預計2025年達175億美元,以-2.1%的年複合成長率 (CAGR) 縮小。還有由於近幾年的技術進步的成果,C型肝炎的治療環境戲劇性地變化,現在以使用直接作用型抗病毒藥物 (DAA) 的高性能用藥法為中心。

本報告提供全球主要9個國家的C型肝炎病毒 (HCV) 治療藥的市場相關分析,疾病概要和今後的流行病學的預測,市場規模趨勢預測,近幾年的市場上的主要動向,市場未滿足需求與未來調查機會,已上市的主要產品的概要,現在臨床實驗中的開發中產品的資訊,主要的推動及阻礙市場要素,今後的市場成長的方向性等。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理
    • 病因
    • 病理生理學
  • 症狀
  • 預後、生活品質 (QoL)

第4章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
  • 全世界的趨勢
    • 受診的發病者數,和患病者的總數
    • 遺傳基因型
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • C型肝炎 (HCV)的流行病學的預測(今後11年份)
    • 患病人數(總數)
    • 受診的患病人數
  • 議論
    • 流行病學的趨勢相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 治療概要
    • 初期診斷與介紹途徑
    • 患者的評估
    • 病毒的評估
  • 治療指南
  • 美國
    • 診斷
    • 治療指南
    • 臨床診療和其範圍
  • (5EU)歐洲主要5個國家
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 巴西
  • 中國

第6章 市場競爭的評估

  • 概要
  • 競爭企業的策略性評估
  • 領導品牌藥 - 直接作用型抗病毒藥物的固定劑量複方藥物 (FDC)
  • 領導品牌藥 - 單一成分的直接作用型抗病毒藥物
  • 領導品牌藥 - 聚乙二醇干擾素、Ribavirin
  • 其他品牌DAA (直接作用型抗病毒藥物)

第7章 未滿足需求與機會分析分析

  • 概要
  • 直接作用型抗病毒藥物 (DAA) 治療流程的整體成本負擔的削減
    • 未滿足需求
    • 差距分析
    • 市場機會
  • C型肝炎的治療機會相關認知度的提高
    • 醫生對C型肝炎的方法選擇的調整
    • 社會全體的認知度
  • 治療獲取的擴大
  • 慢性C型肝炎感染者的診斷率的改善
  • 全病患小組中副作用的發生頻率、重病度的減輕
  • 難治性患者的治癒率的改善
  • 兒童患者中DAA的功效:臨床評估

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
    • 各臨床實驗階段、各相位
  • 臨床實驗中有前途的DAA的收銀機麵條
    • Sofosbuvir/Velpatasvir/Voxilaprevir
    • Glecaprevir/pibrentasvir
    • Asunaprevir/Beclabuvir/Daclatasvir
    • MK-3682及AMK-3682B
    • Odalasvir系用藥法
  • 臨床實驗中的其他醫藥品
    • 現有的作用機制 (MOA) 的實驗性治療
    • 新的作用機制的實驗性治療
    • 主要9個國家以外的臨床實驗

第9章 現在、未來市場參與企業

  • 概要
  • 企業策略概要
  • 企業簡介
    • Gilead Sciences
    • AbbVie
    • Merck
    • Janssen
    • Bristol-Myers Squibb
    • Roche
  • 有前途的醫藥品,其它企業
    • Regulus Therapeutics
    • Presidio Pharmaceuticals
    • Trek Therapeutics

第10章 市場未來展望

  • 全球市場
    • 市場預測
    • 市場促進、阻礙因素:全球性課題
  • 美國
    • 市場預測
    • 近幾年主要的事件
    • 市場促進、阻礙因素
  • 歐洲主要5個國家 (法國、德國、義大利、西班牙、英國)
  • 日本
  • 巴西
  • 中國

第11章 附錄

目錄

Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), Hepatocellular carcinoma (HCC), and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide.

The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug. During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). Moreover, the hepatitis C market is set to experience a steady decline, falling from $21.7 billion in 2015 to $17.5 billion by 2025, representing a negative compound annual growth rate of 2.1%.

The report "PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025" states that this deterioration in sales, which will occur across the nine major markets (9MM) of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China, will be due to recent advances made in hepatitis C treatment, which have resulted in high cure rates and reduced adverse effects for the vast majority of individuals with chronic hepatitis C infection.

The main market for direct-acting antivirals (DAAs) curing patients of hepatitis C in 2015 was the US, contributing to over 60% of the total market size. However, declining patient populations and unusually high DAA treatment rates in 2015 will reduce the disease prevalence in the US market to a more sustainable level, with the US contributing only 48% of sales in the 9MM by 2025.

Companies reviewed in this report: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen / Johnson & Johnson, Merck, Roche.

Scope

  • Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered.
  • Topline hepatitis C market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model.
  • Key topics covered include dynamics in the number of prevalent cases during the forecast, market characterization, unmet needs, and company strategies.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global hepatitis C marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the hepatitis C market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis and Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. Diagnosed Incidence and Total Prevalence
    • 4.3.2. Genotype
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used Tables
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast of HCV (2015-2025)
    • 4.5.1. Total Prevalent Cases
    • 4.5.2. Diagnosed Prevalent Cases
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis Overview
    • 5.1.1. Initial Diagnosis and Referral
    • 5.1.2. Patient Assessment
    • 5.1.3. Viral Assessment
  • 5.2. Treatment Guildines
  • 5.3. US
    • 5.3.1. Diagnosis
    • 5.3.2. Treatment Guidelines
    • 5.3.3. Clinical Practice and Coverage
  • 5.4. 5EU
    • 5.4.1. Diagnosis Overview
    • 5.4.2. Treatment Guidelines Overview
  • 5.5. France
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Germany
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. Italy
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Spain
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. UK
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice
  • 5.10. Japan
    • 5.10.1. Diagnosis
    • 5.10.2. Clinical Practice
  • 5.11. Brazil
    • 5.11.1. Diagnosis
    • 5.11.2. Clinical Practice
  • 5.12. China
    • 5.12.1. Diagnosis
    • 5.12.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Major Brands - Fixed-Dose Combination Direct-Acting Antivirals
    • 6.3.1. Harvoni (Ledipasvir/Sofosbuvir)
    • 6.3.2. Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir) and Technivie (Ombitasvir/Paritaprevir/Ritonavir)
    • 6.3.3. Zepatier (Elbasvir/Grazoprevir)
    • 6.3.4. Epclusa (Sofosbuvir/Velpatasvir)
  • 6.4. Major Brands - Single Component Direct-Acting Antivirals
    • 6.4.1. Sovaldi (Sofosbuvir)
    • 6.4.2. Daklinza (Daclatasvir)
    • 6.4.3. Olysio (Simeprevir)
  • 6.5. Major Brands - Peginterferon and Ribavirin
    • 6.5.1. Pegasys (Peginterferon alfa-2a) and PegIntron (Peginterferon alfa-2b)
    • 6.5.2. Copegus, Rebetol, and Generic Ribavirin
  • 6.6. Other Branded Direct-Acting Antivirals
    • 6.6.1. Incivek (Telaprevir) and Victrelis (Boceprevir)
    • 6.6.2. Sunvepra (Asunaprevir)
    • 6.6.3. Exviera (Dasabuvir)
    • 6.6.4. Vanihep (Vaniprevir)

7. Unmet Needs and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Reducing the Overall Cost Burden of Direct-Acting Antiviral Treatment Algorithms
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Increasing Awareness of Hepatitis C Treatment Opportunities
    • 7.3.1. Adjusting the Approaches Physicians Take with Hepatitis C
    • 7.3.2. Awareness in the General Population
  • 7.4. Expanding Treatment Access
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Improving Diagnosis Rates in Patients with Chronic Hepatitis C Infection
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Reducing Frequency and Severity of Adverse Events in All Patient Groups
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Enhanced Cure Rates in Difficult-to-Treat Patients
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity
  • 7.8. Clinical Evalulation of Direct-Acting Antiviral Efficacy in Pediatric Patients
    • 7.8.1. Unmet Need
    • 7.8.2. Gap Analysis
    • 7.8.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Status and Phase
  • 8.3. Promising DAA Regimens in Clinical Development
    • 8.3.1. Sofosbuvir/Velpatasvir/Voxilaprevir
    • 8.3.2. Glecaprevir/pibrentasvir
    • 8.3.3. Asunaprevir/Beclabuvir/Daclatasvir
    • 8.3.4. MK-3682A and MK-3682B
    • 8.3.5. Odalasvir-Based Regimens
  • 8.4. Other Products in Clinical Development
    • 8.4.1. Investigational Therapies with Established MOAs
    • 8.4.2. Investigational Therapies with Novel MOAs
    • 8.4.3. Clinical Development Outside 9MM

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Gilead Sciences
    • 9.3.2. AbbVie
    • 9.3.3. Merck
    • 9.3.4. Janssen
    • 9.3.5. Bristol-Myers Squibb
    • 9.3.6. Roche
  • 9.4. Additional Companies with Promising Drugs
    • 9.4.1. Regulus Therapeutics
    • 9.4.2. Presidio Pharmaceuticals
    • 9.4.3. Trek Therapeutics

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. 5EU
    • 10.3.2. France
    • 10.3.3. Germany
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. UK
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Brazil
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. China
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Patient Populations
    • 11.4.2. Drugs Included in Each Therapeutic Class
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Generic Erosion
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs and Payers Interviewed for this Report
    • 11.5.1. KOLs
    • 11.5.2. Payers
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analysts
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologists
    • 11.7.4. Global Director of Therapy Analysis and Epidemiology
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Modes of HCV Transmission
  • Table 2: Symptoms of Acute and Chronic HCV Infection
  • Table 3: Risk Factors and Comorbidities Associated with HCV Infection
  • Table 4: 9MM, Anti-HCV+ Total Prevalence from 1988-2015
  • Table 5: Hepatitis C Virus Genotype Description
  • Table 6: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases
  • Table 7: 9MM, Sources Used to Forecast HCV RNA+ Total Prevalent Cases
  • Table 8: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases by HCV Genotypes
  • Table 9: 9MM, Sources Used to Forecast HCV/HIV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases
  • Table 10: 9MM, Sources Used to Forecast HCV/HBV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases
  • Table 11: 9MM, Sources Used to Forecast Anti-HCV+ Diagnosed Prevalent Cases
  • Table 12: 9MM, Sources Used to Forecast HCV RNA+ Diagnosed Prevalent Cases
  • Table 13: 9MM, Sources Used for Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status
  • Table 14: 9MM, Sources Not Used in Epidemiological Forecast for Anti-HCV+ Total Prevalent Cases
  • Table 15: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 16. 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015 85

  • Table 17: 9MM, Anti-HCV+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015
  • Table 18: 9MM, Anti-HCV+ Total Prevalent Cases, by HCV Genotype, All Ages, N (Row %), Both Sexes, 2015
  • Table 19: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 20. 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015 94

  • Table 21: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015
  • Table 22: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 23: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015
  • Table 24: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015
  • Table 25: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 26: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015
  • Table 27: 9MM, HCV RNA+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015
  • Table 28: HCV Genotypes Prevalent in the 9MM
  • Table 29: General Standard of Care by HCV Genotype in 2015
  • Table 30: Treatment Guidelines for Hepatitis C
  • Table 31: Country Profile - US
  • Table 32: Recommended Treatment Options for Treatment-Naive Patients in the US, 2016
  • Table 33: Country Profile - 5EU
  • Table 34: Recommended Treatment Options for Treatment-naive Patients in the 5EU, 2016
  • Table 35: Country Profile - Japan
  • Table 36: Country Profile - Brazil
  • Table 37: Country Profile - China
  • Table 38: Leading Treatments for Hepatitis C, 2016
  • Table 39: Harvoni - Clinical Trials Supporting Regulatory Approval
  • Table 40: Product Profile - Harvoni
  • Table 41: Key Clinical Trials of Gilead's Harvoni
  • Table 42: Safety of Harvoni - Most Common AEs
  • Table 43: Harvoni SWOT Analysis, 2016
  • Table 44: Global Sales Forecasts ($m) for Harvoni, 2015-2025
  • Table 45: Viekira Pak and Technivie - Key Clinical Trials Supporting Regulatory Approval
  • Table 46: Product Profile - Viekira Pak and Technivie
  • Table 47: Efficacy of Viekira Pak and Technivie - SVR12, Key Phase III and Phase II Studies
  • Table 48: Safety of Viekira Pak and Technivie - Most Common AEs
  • Table 49: Viekira Pak and Technivie SWOT Analysis, 2016
  • Table 50: Global Sales Forecast ($m) for Viekira Pak, 2015-2025
  • Table 51: Zepatier - Key Clinical Trials Supporting Regulatory Approval
  • Table 52: Product Profile - Zepatier
  • Table 53: Efficacy of Zepatier - SVR12, Key Phase III and Phase II Clinical Trials
  • Table 54: Treatment-Emergent Amino Acid Substitutions Among Virologic Failures of Zepatier
  • Table 55: Safety of Zepatier - Most Common AEs
  • Table 56: Zepatier SWOT Analysis, 2016
  • Table 57: Global Sales Forecasts ($m) for Zepatier, 2015-2025
  • Table 58: Key Clinical Trials of Gilead's Epclusa
  • Table 59: Product Profile - Epclusa
  • Table 60: Efficacy of Epclusa - SVR12, Key Phase III Trials
  • Table 61: Safety of Epclusa - Most Common AEs
  • Table 62: Epclusa SWOT Analysis, 2016
  • Table 63: Global Sales Forecasts ($m) for Epclusa, 2015-2025
  • Table 64: Sovaldi - Clinical Trials Supporting Regulatory Approval
  • Table 65: Product Profile - Sovaldi
  • Table 66: Efficacy of Sovaldi - SVR12, Key Phase III Trials
  • Table 67: Safety of Sovaldi - Most Common AEs
  • Table 68: Sovaldi SWOT Analysis, 2016
  • Table 69: Global Sales Forecast ($m) for Sovaldi, 2015-2025
  • Table 70: Daklinza - Key Clinical Trials Supporting Regulatory Approval
  • Table 71: Product Profile - Daklinza
  • Table 72: Efficacy of Daklinza - SVR12, Key Phase IIb and III Trials
  • Table 73: Safety of Daklinza - Most Common AEs
  • Table 74: Daklinza SWOT Analysis, 2016
  • Table 75: Global Sales Forecast ($m) for Daklinza, 2015-2025
  • Table 76: Olysio - Key Clinical Trials Supporting Regulatory Approval
  • Table 77: Product Profile - Olysio
  • Table 78: Efficacy of Olysio - SVR12, Key Phase III and Phase II Trials
  • Table 79: Safety of Olysio - Most Common AEs in Clinical Trials
  • Table 80: Olysio SWOT Analysis, 2016
  • Table 81: Global Sales Forecasts ($m) for Olysio, 2015-2025
  • Table 82: Product Profile - Pegasys
  • Table 83: Product Profile - PegIntron
  • Table 84: Efficacy of Pegasys with or without Ribavirin Compared with Interferon Alfa-2b
  • Table 85: Efficacy of PegIntron Compared With Interferon Alfa-2b
  • Table 86: Pegasys and PegIntron SWOT Analysis, 2016
  • Table 87: Global Sales Forecast ($m) for Pegasys, 2015-2025
  • Table 88: Global Sales Forecast ($m) for PegIntron, 2015-2025
  • Table 89: Ribavirin SWOT Analysis, 2016
  • Table 90: Global Sales Forecast ($m) for Copegus, 2015-2025
  • Table 91: Global Sales Forecast ($m) for Rebetol, 2015-2025
  • Table 92: Summary of Other Branded DAAs, 2016
  • Table 93: Unmet Needs and Opportunities in Chronic Hepatitis C
  • Table 94: Hepatitis C Virus Infection - Late-Stage Pipeline, 2016
  • Table 95: Key Clinical Trials of Gilead's Sofosbuvir/Velpatasvir/Voxilaprevir Combination
  • Table 96: Product Profile - Sofosbuvir/Velpatasvir/Voxilaprevir
  • Table 97: Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Phase II Clinical Trials
  • Table 98: Sofosbuvir/Velpatasvir/Voxilaprevir SWOT Analysis, 2016
  • Table 99: Global Sales Forecast ($m) for Sofosbuvir/Velpatasvir/Voxilaprevir, 2015-2025
  • Table 100: Phase III Clinical Trials of AbbVie's Glecaprevir/Pibrentasvir Combination
  • Table 101: Product Profile - Glecaprevir/Pibrentasvir
  • Table 102: Efficacy of Glecaprevir/Pibrentasvir in Phase II Trials
  • Table 103: Most Common AEs of Glecaprevir/Pibrentasvir in Phase II Trials
  • Table 104: Glecaprevir/Pibrentasvir SWOT Analysis, 2016
  • Table 105: Global Sales Forecast ($m) for Glecaprevir/Pibrentasvir, 2015-2025
  • Table 106: Phase III Clinical Trials of BMS's Asunaprevir/Beclabuvir/Daclatasvir
  • Table 107: Product Profile - Asunaprevir/Beclabuvir/Daclatasvir
  • Table 108: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Phase III Clinical Trials
  • Table 109: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Japanese Patients
  • Table 110: Asunaprevir/Beclabuvir/Daclatasvir SWOT Analysis, 2016
  • Table 111: Global Sales Forecast ($m) for Asunaprevir/Beclabuvir/Daclatasvir, 2015-2025
  • Table 112: On-Going Phase II Clinical Trials of MK-3682A and MK-3682B
  • Table 113: Product Profile - MK-3682A and MK-3682B
  • Table 114: Efficacy of MK-3682A and MK-3682B in Phase II Trials
  • Table 115: MK-3682A and MK-3682B SWOT Analysis, 2016
  • Table 116: Global Sales Forecasts ($m) for MK-3682A and MK-3682B, 2015-2025
  • Table 117: Phase II Clinical Trials involving Achillion and Janssen's Odalasvir
  • Table 118: Product Profile - AL-335/odalasvir/simeprevir
  • Table 119: AL-335/Odalasvir/Simeprevir SWOT Analysis, 2016
  • Table 120: Global Sales Forecast ($m) for AL-335/Odalasvir/Simeprevir, 2015-2025
  • Table 121: Other Products in Clinical Development for HCV Infection, 2016
  • Table 122: Clinical Development outside 9MM, 2016
  • Table 123: Key Companies in the HCV Marketplace in the 9MM, 2016
  • Table 124: Gilead's HCV Portfolio Assessment, 2016
  • Table 125: AbbVie's HCV Portfolio Assessment, 2016
  • Table 126: Merck's HCV Portfolio Assessment, 2016
  • Table 127: Janssen's HCV Portfolio Assessment, 2016
  • Table 128: BMS' HCV Portfolio Assessment, 2016
  • Table 129: Roche's HCV Portfolio Assessment, 2016
  • Table 130: Regulus' HCV Portfolio Assessment, 2016
  • Table 131: Presidio's HCV Portfolio Assessment, 2016
  • Table 132:Trek Therapeutics' HCV Portfolio Assessment, 2016
  • Table 133: Global (9MM) Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 134: 9MM Chronic Hepatitis C Market - Drivers and Barriers, 2015-2025
  • Table 135: US Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 136: Key Events Impacting Sales for Chronic Hepatitis C in the US, 2015-2025
  • Table 137: Chronic Hepatitis C Market - Drivers and Barriers in the US, 2015-2025
  • Table 138: 5EU Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 139: Key Events Impacting Sales for Chronic Hepatitis C in the 5EU, 2015-2025
  • Table 140: Chronic Hepatitis C Market - Drivers and Barriers in the 5EU, 2015-2025
  • Table 141: France Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 142: Key Events Impacting Sales for Chronic Hepatitis C in France, 2015-2025
  • Table 143: Chronic Hepatitis C Market - Drivers and Barriers in France, 2015-2025
  • Table 144: Germany Sales Forecasts ($m) for Hepatitis C, 2015-2025
  • Table 145: Key Events Impacting Sales for Chronic Hepatitis C in Germany, 2015-2025
  • Table 146: Chronic Hepatitis C Market - Drivers and Barriers in Germany, 2015-2025
  • Table 147: Italy Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 148: Key Events Impacting Sales for Chronic Hepatitis C in Italy, 2015-2025
  • Table 149: Chronic Hepatitis C Market - Drivers and Barriers in Italy, 2015-2025
  • Table 150: Spain Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 151: Key Events Impacting Sales for Chronic Hepatitis C in Spain, 2015-2025
  • Table 152: Chronic Hepatitis C Market - Drivers and Barriers in Spain, 2015-2025
  • Table 153: UK Sales Forecasts ($m) for Hepatitis C, 2015-2025
  • Table 154: Key Events Impacting Sales for Chronic Hepatitis C in the UK, 2015-2025
  • Table 155: Chronic Hepatitis C Market - Drivers and Barriers in the UK, 2015-2025
  • Table 156: Japan Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 157: Key Events Impacting Sales for Chronic Hepatitis C in Japan, 2015-2025
  • Table 158: Chronic Hepatitis C Market - Drivers and Barriers in Japan, 2015-2025
  • Table 159: Brazil Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 160: Key Events Impacting Sales for Chronic Hepatitis C in Brazil, 2015-2025
  • Table 161: Chronic Hepatitis C Market - Drivers and Barriers in Brazil, 2015-2025
  • Table 162: China Sales Forecast ($m) for Hepatitis C, 2015-2025
  • Table 163: Key Events Impacting Sales for Chronic Hepatitis C in China, 2015-2025
  • Table 164: Chronic Hepatitis C Market - Drivers and Barriers in China, 2015-2025

Table 165 Key Historical and Projected Launch Dates for Chronic Hepatitis C 480

Table 166 Key Historical and Projected Patent Expiry Dates for Chronic Hepatitis C 481

  • Table 167: High Prescribers Surveyed

List of Figures

  • Figure 1: HCV Genome and Polyprotein Composition
  • Figure 2: HCV Lifecycle Overview
  • Figure 3: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 4: 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N, 2015
  • Figure 5: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, by Sex, N, 2015
  • Figure 6: 9MM, Age-Standardized Anti-HCV+ Total Prevalence, All Ages, by Sex, %, 2015
  • Figure 7: 9MM, HIV and HBV Co-Infections Among Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, 2015
  • Figure 8: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 9: 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N, 2015
  • Figure 10: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, N, 2015
  • Figure 11: 9MM, Age-Standardized HCV RNA+ Total Prevalence, All Ages, by Sex, %, 2015
  • Figure 12: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 13: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N, 2015
  • Figure 14: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015
  • Figure 15: 9MM, Age-Standardized Anti-HCV+ Diagnosed Prevalence, All Ages, by Sex, %, 2015
  • Figure 16: 9MM, Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status, All Ages, Both Sexes, N, 2015
  • Figure 17: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 18: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N, 2015
  • Figure 19: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015
  • Figure 20: 9MM, Age-Standardized HCV RNA+ Diagnosed Prevalence, All Ages, by Sex, %, 2015
  • Figure 21: Hepatitis C - Clinical Trials by Status and Phase, 2016
  • Figure 22: HCV Infection Therapies - Phase II-III Pipeline, 2016
  • Figure 23: Competitive Assessment of Late-Stage Pipeline Agents for HCV Infection, 2015-2025
  • Figure 24: Clinical and Commercial Positioning of Sofosbuvir/Velpatasvir/Voxilaprevir
  • Figure 25: Clinical and Commercial Positioning of Glecaprevir/Pibrentasvir
  • Figure 26: Clinical and Commercial Positioning of Asunaprevir/Beclabuvir/Daclatasvir
  • Figure 27: Clinical and Commercial Positioning of MK-3682A and MK-3682B
  • Figure 28: Clinical and Commercial Positioning of Odalasvir-Based Regimens
  • Figure 29: Company Market Share in HCV, 2015 and 2025
  • Figure 30: Company Portfolio Gap Analysis in HCV, 2015-2025
  • Figure 31: Annual Global (9MM) Sales of DAAs, by Region, in 2015 and 2025
  • Figure 32: Annual Global (9MM) Sales of DAAs, by Brand, in 2015 and 2025
  • Figure 33: Annual Sales of DAAs in the US in 2015 and 2025
  • Figure 34: Annual Sales of DAAs in the 5EU in 2015 and 2025
  • Figure 35: Annual Sales of DAAs in France in 2015 and 2025
  • Figure 36: Annual Sales of DAAs in Germany in 2015 and 2025
  • Figure 37: Annual Sales of DAAs in Italy in 2015 and 2025
  • Figure 38: Annual Sales of DAAs in Spain in 2015 and 2025
  • Figure 39: Annual Sales of DAAs in the UK in 2015 and 2025
  • Figure 40: Annual Sales of DAAs in Japan in 2015 and 2025
  • Figure 41: Annual Sales of DAAs in Brazil in 2015 and 2025
  • Figure 42: Annual Sales of DAAs in China in 2025
Back to Top